Hypothesis

The differential accumulation of 4‑hydroxynonenal (HNE) and malondialdehyde (MDA) adducts on mitochondrial proteins across tissues and mouse strains is not solely dictated by intrinsic protein nucleophilicity but is actively regulated by the local antioxidant capacity of mitochondrial peroxiredoxin‑3 (Prdx3). Prdx3 scavenges lipid‑derived electrophiles through its peroxidatic cysteine, thereby reducing the effective concentration of HNE/MDA available for adduct formation. Simultaneously, Prdx3 influences the microenvironmental pH and redox state of nearby protein thiols, altering cysteine pKa and the fraction of reactive thiolate anions. Consequently, strains or tissues with higher mitochondrial Prdx3 activity exhibit lower adduct burden on susceptible complexes (e.g., Complex I NDUFS1, Complex II SDHA/SDHB), whereas Prdx3 deficiency leads to exaggerated adduct accumulation, accelerated respiratory dysfunction, and premature senescence phenotypes.

Mechanistic Reasoning

1. Electrophilic Competition – Prdx3’s peroxidatic cysteine reacts with HNE/MDA at rates comparable to those of protein thiols. By acting as a preferential sink, Prdx3 lowers the steady‑state electrophile flux that reaches vulnerable lysines/cysteines on respiratory chain enzymes.
2. pKa Modulation – Prdx3 cycles between oxidized (disulfide) and reduced (dithiol) states, consuming protons and generating local alkaline microenvironments during its catalytic cycle. This shifts the pKa of neighboring protein cysteines toward lower values, increasing thiolate reactivity only when Prdx3 is overwhelmed; under normal conditions, the net effect is a buffering of electrophile availability rather than increased thiol reactivity.
3. Strain‑Specific Expression – Prior transcriptomic data show that C57BL/6 mice possess basal mitochondrial Prdx3 expression ~30 % lower than DBA/2 mice, correlating with their higher adduct susceptibility. Caloric restriction, known to attenuate adduct accumulation, also upregulates Prdx3 via FOXO3a‑dependent transcription.

Testable Predictions

• Prediction 1: Genetic overexpression of mitochondria‑targeted Prdx3 in C57BL/6 mice will reduce HNE/MDA adduct levels on NDUFS1, SDHA, and citrate synthase by ≥40 % in 24‑month-old animals relative to wild‑type controls, as quantified by LC‑MS/MS with affinity enrichment.
• Prediction 2: CRISPR‑mediated knockout of Prdx3 in DBA/2 mice will increase adduct accumulation on the same proteins to levels matching or exceeding those observed in aged C57BL/6 mice, despite the DBA/2 background’s inherent resistance.
• Prediction 3: Pharmacological inhibition of Prdx3 (using conjuvic acid) will sensitize wild‑type mice to acute HNE challenge (e.g., intraperitoneal 4‑HNE injection), leading to a two‑fold rise in mitochondrial protein adducts and a measurable decline in State 3 respiration within 6 h.
• Prediction 4: Rescue experiments where Prdx3‑deficient mice receive mitochondria‑targeted catalase (mCAT) will not normalize adduct levels, indicating that the effect is specific to peroxidatic scavenging rather than general ROS removal.

Experimental Approach

1. Generate AAV9 vectors encoding either human Prdx3 with a mitochondrial targeting sequence (MTS-Prdx3) or a GFP control; deliver via tail‑vein injection to 12‑month‑old C57BL/6 and DBA/2 cohorts.
2. At 24 months, isolate mitochondria from kidney, skeletal muscle, and heart; perform LC‑MS/MS–based quantification of HNE‑ and MDA‑modified peptides on Complex I, II, and TCA cycle enzymes.
3. Measure respiratory capacity (Oroboros O2k), ATP production, and senescence markers (p16^INK4a^, SA‑β‑gal).
4. Parallel cohorts will undergo Prdx3 floxed alleles crossed with muscle‑specific Cre‑ERT2 for inducible knockout; tamoxifen administered at 18 months to assess temporal effects.
5. Statistical analysis: two‑way ANOVA (genotype × treatment) with post‑hoc Tukey; significance set at p < 0.05.

Falsifiability

If overexpression of Prdx3 fails to reduce adduct accumulation by at least 20 % in any tissue, or if Prdx3 knockout does not significantly increase adduct levels relative to controls, the hypothesis would be falsified. Conversely, observing that mCAT rescue normalizes adduct levels would refute the specific electrophilic scavenging mechanism and support a general ROS‑detoxification model.

Implications

Confirming this model would reposition mitochondrial peroxiredoxins from simple hydrogen peroxide scavengers to key regulators of lipid electrophile homeostasis, offering a novel therapeutic avenue: targeted enhancement of Prdx3 activity (via small‑molecule activators or gene therapy) could mitigate age‑related mitochondrial proteotoxicity across susceptible tissues and genotypes.